TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00887354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Weekly: Administered orally~Daily: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly: Administered orally~Daily: Administered subcutaneously

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Approximately 500 to 1000 mg/day administered orally throughout study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Approximately 500 to 1000 mg/day administered orally throughout study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Approximately 800 International Units per day (IU/day) administered orally throughout study.
Study: NCT00350636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin topical gel
Description: 1 application daily to skin for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo topical gel
Description: 1 application daily to skin for 12 weeks
Study: NCT01710033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tables twice daily (BID) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 5 mg BID
Description: CP-690,550 5 mg BID for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 15 mg BID
Description: CP-690,550 15 mg BID for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 30 mg BID
Description: CP-690,550 30 mg BID for 28 days
Study: NCT01356966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo pills PO BID for12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folate
Description: Folate 1 mg daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folate
Description: Folate 1 mg daily for 12 weeks
Study: NCT00772772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
Study: NCT01550796

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: 250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: 250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
Study: NCT02307955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: firefly

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Study: NCT02468869

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication skills training empathy skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication skills training information structuring skills
Study: NCT02981342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally
Study: NCT01472250

Intervention type: DRUG
Intervention: Clinical chemo-drugs
Description: Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel
Study: NCT03987074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally once daily
Study: NCT03820024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Feedback Messages
Description: Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
Study: NCT03100370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Anodal Stimulation
Description: 2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
Study: NCT01638598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo
Description: matching placebo in each dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: BI 1021958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo
Description: matching placebo in each dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: BI 1021958
Study: NCT03100370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Anodal Stimulation
Description: 2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Anodal Stimulation
Description: 2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Anodal Stimulation
Description: 2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
Study: NCT01638598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: BI 1021958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: BI 1021958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: BI 1021958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo
Description: matching placebo in each dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo
Description: matching placebo in each dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo
Description: matching placebo in each dose level
Study: NCT00998309

Intervention type: DRUG
Intervention: Azithromycin SR
Description: Zithromax SR 2g, taking once for treatment.
Study: NCT02679638

Intervention type: OTHER
Intervention: Factors and perceptions questionnaire
Description: A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.

Intervention type: OTHER
Intervention: Factors and perceptions questionnaire
Description: A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
Study: NCT02898961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin
Description: In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion.
Study: NCT02679638

Intervention type: OTHER
Intervention: Factors and perceptions questionnaire
Description: A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.

Intervention type: OTHER
Intervention: Factors and perceptions questionnaire
Description: A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.

Intervention type: OTHER
Intervention: Qualitative interview
Description: Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.

Intervention type: OTHER
Intervention: Qualitative interview
Description: Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
Study: NCT00735397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
Study: NCT00994578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS
Description: Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE
Description: Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS/COPE
Description: Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
Study: NCT04225910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA
Description: all the patients will receive 225Ac-PSMA RLT for 2 cycles. The dosage will be calculated according to 100KBq/kg body weight. The drug will be administered by vein injection.
Study: NCT00000378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 12 week trial dose up to 200mgs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: 12 week trial dose adjusted to therapeutic level
Study: NCT02072343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No-DCCM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No-DCCM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCCM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCCM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water 5ml in tracheal tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water 5ml in tracheal tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water 10ml in tracheal tube
Study: NCT00419315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Care Management
Description: Care management for alcohol dependence with a focus on pharmacotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care included a referral to a specialty addiction treatment program.
Study: NCT02072343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water 10ml in tracheal tube
Study: NCT03616717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
Study: NCT04420273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSE educational intervention
Description: Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control:Healthy Living
Description: Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
Study: NCT01146756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
Study: NCT02847988

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical Stimulation (NMES)
Description: Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
Study: NCT04363957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brachytherapy video
Description: Patients will watch a video that contains information about brachytherapy
Study: NCT00330928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy (NIRS) Imaging
Description: Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravascular ultrasound (IVUS)
Description: Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
Study: NCT03224871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional IL-2
Description: High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional IL-2
Description: High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
Study: NCT05254561

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional antigen immunotherapy
Description: Randomized double-blinded comparative effectiveness and safety clinical trial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional antigen immunotherapy
Description: Randomized double-blinded comparative effectiveness and safety clinical trial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional antigen immunotherapy
Description: Randomized double-blinded comparative effectiveness and safety clinical trial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional antigen immunotherapy
Description: Randomized double-blinded comparative effectiveness and safety clinical trial
Study: NCT03094858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone with prompts
Description: Smartphone will be used to prompt randomly selected participants in intervention group to be active

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wristband
Description: Wristband will monitor activity of all participants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristband
Description: Wristband will monitor activity of all participants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
Study: NCT03859739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8558
Description: Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8558
Description: Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8558
Description: Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8558
Description: Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
Study: NCT05709522

Intervention type: BEHAVIORAL
Intervention: Neurocognitive tools
Description: Neurocognitve and psychological tools

Intervention type: BEHAVIORAL
Intervention: Neurocognitive tools
Description: Neurocognitve and psychological tools
Study: NCT01158144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel/Carboplatin
Description: Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
Study: NCT00390481

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EC-IC Bypass in the COSS study
Description: EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.